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Abstract
Cross-species transmissions of viruses from animals to humans are at the origin of major
human pathogenic viruses. While the role of ecological and epidemiological factors in the
emergence of new pathogens is well documented, the importance of host factors is often
unknown. Chimpanzees are the closest relatives of humans and the animal reservoir at the
origin of the human AIDS pandemic. However, despite being regularly exposed to monkey
lentiviruses through hunting, chimpanzees are naturally infected by only a single simian
immunodeficiency virus, SIVcpz. Here, we asked why chimpanzees appear to be protected
against the successful emergence of other SIVs. In particular, we investigated the role of
the chimpanzee APOBEC3 genes in providing a barrier to infection by most monkey lentivi-
ruses. We found that most SIV Vifs, including Vif from SIVwrc infecting western-red colobus,
the chimpanzee’s main monkey prey in West Africa, could not antagonize chimpanzee
APOBEC3G. Moreover, chimpanzee APOBEC3D, as well as APOBEC3F and APO-
BEC3H, provided additional protection against SIV Vif antagonism. Consequently, lentiviral
replication in primary chimpanzee CD4+ T cells was dependent on the presence of a lenti-
viral vif gene that could antagonize chimpanzee APOBEC3s. Finally, by identifying and
functionally characterizing several APOBEC3 gene polymorphisms in both common chim-
panzees and bonobos, we found that these ape populations encode APOBEC3 proteins
that are uniformly resistant to antagonism by monkey lentiviruses.
Author Summary
Many human pathogens are of zoonotic origin, meaning they originated in animals. This
includes HIV-1, the cause of the human AIDS pandemic, which is the result of cross-
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species transmissions of lentiviruses from chimpanzees and gorillas. However, little is
known about the host factors that provide natural protection against viral emergence in a
new species. Chimpanzees, which are humans’ closest relatives, harbor only a single lenti-
viral lineage, despite their frequent exposure to lentiviruses that infect monkeys on which
they prey. Here, we investigate the capacity of the accessory protein Vif from different pri-
mate lentiviruses to antagonize the APOBEC3 antiviral gene family found in chimpanzees.
We found that the Vif protein from most monkey lentiviruses was not able to antagonize
chimpanzee APOBEC3G. Furthermore, other APOBEC3 proteins from chimpanzees were
also resistant to Vif antagonism. Finally, we showed that, despite polymorphism in the
APOBEC3 genes, common chimpanzee and bonobo populations are uniformly resistant to
monkey lentiviral Vif antagonism. Our results are consistent with the hypothesis that the
host APOBEC3 antiviral proteins protect chimpanzees against many HIV-related viruses
commonly found in monkeys.
Introduction
Although lentiviruses are widespread in African monkeys, there have only been a few docu-
mented cases of cross-species transmission and lentiviral emergence into hominoids [1]. Chim-
panzees are of particular interest because their lentivirus, SIVcpz, lies at the root of all HIV-1
infections [2]. SIVcpz has a complex evolutionary history as it resulted from the cross-species
transmission and recombination of SIVrcm from red-capped mangabeys and SIVmus/mon/
gsn from guenons [3,4]. However, only central and eastern chimpanzees are infected by
SIVcpz, while western and Nigerian-Cameroonian chimpanzees as well as bonobos seem cur-
rently free of any lentiviral infection [1,5,6]. The fact that chimpanzees are infected by only a
single lentiviral lineage is surprising given that they are exposed to SIVs that are present at high
prevalence in their monkey prey [6,7]. Moreover, there have been multiple viral cross-species
transmissions of simian foamy virus (SFV) and simian T-lymphotropic virus (STLV) to chim-
panzees from their main prey, the western-red colobus [8–10], yet, no infection with this mon-
key species’ lentivirus, SIVwrc, has been documented in chimpanzees [6,7]. Overall, this
suggests that there are host factors, rather than solely epidemiological or ecological barriers,
that protect chimpanzees against the emergence of new lentiviral infections.
There have been four independent transmissions of HIV-1 into humans that originated
from SIVcpz; two of these transmissions had their immediate source in chimpanzees (HIV-1
groups M and N), while two others passed through gorillas before infecting humans (HIV-1
groups O and P) [2,11]. HIV-2, on the other hand, is the result of cross-species transmissions
of SIVsmm from sooty mangabeys to humans [2]. While SIVsmm has jumped to humans on
over nine independent occasions, neither the equivalent SIVsmm infection of chimpanzees nor
any other SIV other than the recombinant virus that gave rise to SIVcpz has been reported in
apes. As chimpanzees are the closest relatives of humans, the mechanisms governing their sus-
ceptibility or resistance to lentiviruses have direct relevance for the potential of additional pri-
mate lentiviruses to adapt to hominoids and subsequently spread in humans.
Host restriction factors are intrinsic blocks to viral replication [12,13]. Therefore, to com-
plete their lifecycle, viruses encode antagonists that target these innate immune factors. These
antagonistic relationships have led to genetic conflicts driving the evolution and specificities of
virus-host interactions, which may impose potent species barriers to cross-species transmission
[12]. APOBEC3G is one of the antiviral proteins that have been implicated in the species-speci-
ficity of lentiviruses, although the role of APOBEC3G as a species barrier has been mainly
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investigated in experimental cross-species transmissions [14–17]. Moreover, there are at least
four genes from the APOBEC3 gene family (APOBEC3D, F, G, and H) that potently block the
lentiviral life cycle in the absence of the specific viral antagonist Vif (reviewed in [18,19]). Vif
primarily counteracts the APOBEC3s by binding the host protein and targeting it for proteaso-
mal degradation by recruiting an E3 ubiquitin ligase complex. Although vif is highly diverse
within and between SIV and HIV lineages, it is present in all primate lentiviruses and has an
ancient and conserved role in antagonizing the host APOBEC3G protein [20].
Here, we examined why chimpanzees harbor only a single SIV lineage despite being fre-
quently exposed to various SIVs that infect their prey species. We show that Vif from diverse
lentiviruses is incapable of antagonizing chimpanzee APOBEC3G. Moreover, additional chim-
panzee APOBEC3 family members, especially APOBEC3D, also provide blocks to lentiviral
replication. Consequently, we find that the potential of a lentivirus to replicate in primary
chimpanzee CD4+ T cells is governed by its accessory protein Vif. Our data suggest that reten-
tion and evolution of the APOBEC3 family, where several host proteins are antagonized by a
single viral protein at different motifs, set up a diverse battleground against viruses, which may
overall enhance the protection of the host against viral emergence. Finally, we show that the
APOBEC3 genes are polymorphic in common chimpanzees and bonobos, but that the popula-
tions are similarly resistant to lentiviruses with various vif. Overall, we propose that the restric-
tion imposed by the APOBEC3 family of host restriction factors is a crucial mechanism by
which common chimpanzees and bonobos may be naturally protected against most lentiviral
cross-species transmissions.
Results
Vif from most monkey lentiviruses do not have the capacity to
antagonize chimpanzee APOBEC3G
Chimpanzees have overlapping ranges with many monkeys [21] that are widely and commonly
infected by lentiviruses [1]. Each SIV bears a lineage-specific vif whose sequence varies greatly
between lentiviral lineages (Fig 1A). It was previously shown that the inclusion of SIVmac vif
in HIV-1 is necessary to experimentally generate a simian-tropic HIV-1 in rhesus macaques
[14,15]. Moreover, in populations of African green monkeys (AGMs) naturally infected by
SIVs, vif co-evolved with APOBEC3G polymorphisms in the different AGM species to main-
tain antagonism [17]. In addition, we previously found that adaptation of SIVcpz to chimpan-
zees involved the evolution of the vif gene to adapt and counteract chimpanzee APOBEC3G
[4]. Therefore, to determine whether APOBEC3G could be responsible for the lack of transmis-
sion of diverse SIVs to chimpanzees, we tested an extended panel of Vifs from ten lentiviral lin-
eages that spans the diversity of primate lentiviruses for its ability to antagonize chimpanzee
APOBEC3G (Fig 1A). This panel included vif genes from SIVs that infect known preys of
chimpanzees (e.g. SIVwrc from western-red colobus [6,7]). Each SIV vif gene was cloned into
an HIV-1 backbone in place of HIV-1 vif as previously described [20]. The capacity of Vif to
antagonize chimpanzee APOBEC3G was measured in single-round infectivity assays by co-
transfecting the HIV-1 provirus containing an SIV vif gene with a plasmid encoding chimpan-
zee APOBEC3G [22]. The supernatant was normalized for p24gag expression and used to infect
a T cell line, SupT1. The HIV-1 provirus encoded a defective envelope gene and was pseudo-
typed with VSV-G so that only one round of infection was assayed and the provirus expressed
a luciferase gene used as the readout.
In the absence of Vif, chimpanzee APOBEC3G was able to block lentiviral infection (Fig 1B,
white bar). As positive control, this was rescued by SIVcpz Vif, which fully antagonized chim-
panzee APOBEC3G (Fig 1B, black bars, SIVcpzPts and SIVcpzPtt Vifs) [4]. By testing the Vif
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protein from eight different SIVcpz isolates, we found that all of them were also able to antago-
nize chimpanzee APOBEC3G (S1B Fig). However, Vif from other SIV lineages had differential
capacities to antagonize chimpanzee APOBEC3G (Fig 1B, grey bars). As previously shown [4],
Vif from both SIVrcm and SIVmus were able to partially restore infectivity in the presence of
chimpanzee APOBEC3G (17–25% rescue of infectivity), which may have facilitated their evo-
lution and adaptation to chimpanzees. Amongst the other monkey lentiviral vif genes, all but
one lacked the capacity to rescue viral infection in the presence of chimpanzee APOBEC3G
(less than 4% infectivity relative to SIVcpz Vif) (Fig 1B). In particular, the Vif from SIVwrc was
unable to counteract chimpanzee APOBEC3G restriction (Fig 1B). This result alone may
Fig 1. APOBEC3G protects chimpanzees frommost SIV cross-species infections. A, Phylogenetic analysis of Vif proteins from different primate
lentiviruses as described in the Methods. B, Single-round infectivity assay performed in the presence or absence of chimpanzee APOBEC3G; infectivity in
the absence of APOBEC3Gwas normalized to 100%. The graphs show the infectivity values for the average of six to nine infections; error bars indicate the
SD from the mean of these replicates. The infectivity of HIV-1ΔVif (white, negative control), and HIV-1ΔVifΔEnvLuc2 plasmid with vif from SIVcpzPtsTan3 or
SIVcpzPttGab1 (black, positive controls), or vif from SIVs from the given primate species (grey bars) were tested. Each of the Vif proteins was fully capable of
antagonizing at least one APOBEC3 protein using identical proviral expression constructs to those in Fig 1B ([4,17,20] and Fig 2).
doi:10.1371/journal.ppat.1005149.g001
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explain why chimpanzees are not infected by SIVs from one of their most common prey, the
western-red colobus.
As controls, we also examined the Vif-APOBEC3G antagonism in two cases of known
cross-species transmissions, that of SIVagm.ver (or SIVver) into baboons [23] and SIVagm.sab
(or SIVsab) into Patas monkeys [24]. In both cases, the Vif from the donor species (i.e. SIVver
Vif and SIVsab Vif) was capable to overcome the APOBEC3G of the recipient species (i.e.
baboons and Patas monkeys) as well as it overcame the APOBEC3G of its natural host (S2
Fig). A tabulation of other cross-species transmissions of primate lentiviruses (Table 1) indi-
cates that all known natural host switches that occurred were from primate lentiviruses that
had some or full capacity to antagonize their new host APOBEC3G (Table 1 and S2 Fig). This
suggests that at least partial antagonism of APOBEC3G may be a pre-requisite to natural
cross-species infection. On the other hand, APOBEC3G antagonism is not sufficient to allow
cross-species transmission, as other barriers may be involved. For example, SIVsmm Vif was
the only monkey lentiviral protein able to completely antagonize chimpanzee APOBEC3G
(Fig 1B), showing that APOBEC3G cannot explain the lack of infection of chimpanzee popula-
tions with this virus (see below). In summary, the lack of antagonism of APOBEC3G by lenti-
viral Vifs could explain the lack of SIV emergence into chimpanzees of most, but not all SIVs
from monkeys.
The Vif proteins from most monkey SIVs poorly antagonize the antiviral
activity of chimpanzee APOBEC3 proteins
Because other APOBEC3 genes may also be implicated in the Vif-dependent restriction of lenti-
viruses, we tested if vif genes from the various SIV lineages are capable of antagonizing chim-
panzee APOBEC3D, APOBEC3F, and APOBEC3H. APOBEC3D is of particular interest,
because the chimpanzee version of this protein is highly active against lentiviruses, while the
human version has less such activity [25]. Using the single-round assay where exogenous APO-
BEC3 genes are transfected into 293T cells as described in Fig 1B, we confirmed that in the
Table 1. All viruses that naturally jumped the species barrier had some capacity to antagonize the new species APOBEC3G. Sensitivity of APO-
BEC3G (from the recipient host species) to the SIV Vif protein (from the virus that crossed the species barrier); infectivity of viruses produced in the presence
of APOBEC3G is reported as a percentage, relative to infectivity in the absence of APOBEC3G (100%).
SIV Vif Isolates a APOBEC3G b Relative infectivity of viruses c Origin of. . . d Reference e
SIVrcm Chimpanzee 17% SIVcpz Fig 1B
SIVmus Chimpanzee 25% SIVcpz Fig 1B
SIVcpz Human 73% HIV-1 Etienne et al. 2013
SIVcpz Gorilla Minimal SIVgor Letko et al. 2013, D’Arc et al. 2015
SIVgor Human ~85% HIV-1 Letko et al. 2013
SIVsmm Macaques 90% SIVmac Compton et al. 2013
SIVsmm Human 100% HIV-2 Compton et al. 2013
SIVver Baboon 86% SIVver-bab S2 Fig
SIVsab Patas 71% SIVsab-pat S2 Fig
a, Virus from which the vif gene was taken. Vif proteins are from viruses that crossed to a new host species.
b, Host species from which APOBEC3G was taken. APOBEC3G proteins are from recipient host species.
c, Infectivity of viral constructs produced in the presence of APOBEC3G (relative to no APOBEC3G).
d, Virus that resulted from the cross-species transmission event(s).
e, References: Etienne et al. 2013 [4], Compton et al. 2013 [20], Letko et al 2013 [56], D’Arc et al. 2015 [11], others are data from this study (Figs 1B and
S2).
doi:10.1371/journal.ppat.1005149.t001
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absence of Vif, chimpanzee APOBEC3D is more potent than the human APOBEC3D in
restricting a lentivirus (S3A Fig, delta-Vif condition; similar expression level of chimpanzee
and human APOBEC3D in a dose-dependent manner, S3B Fig) [25]. Despite the increased
activity of chimpanzee APOBEC3D relative to the human protein, the Vif protein from two
divergent SIVcpz isolates was able to antagonize chimpanzee APOBEC3D and to rescue viral
infection (Fig 2A, black bars). On the other hand, the Vif protein from six monkey SIV line-
ages, including SIVwrc Vif, was not able to antagonize chimpanzee APOBEC3D (Fig 2A).
Moreover, it was also notable that, although it could readily antagonize chimpanzee APO-
BEC3G, SIVsmm Vif was only poorly active against chimpanzee APOBEC3D (Fig 2A, 15%
capacity versus SIVcpz Vif).
Chimpanzee APOBEC3F and APOBEC3H also reduced lentiviral infectivity in the absence
of Vif, although APOBEC3F restriction was not as strong as the other APOBEC3s (Fig 2B and
2C, white bars). Most monkey SIV lineages encode a Vif that had a moderate activity against
chimpanzee APOBEC3F (Fig 2B), while most Vifs were fully equipped to antagonize chimpan-
zee APOBEC3H (Fig 2C, levels of infectivity similar to SIVcpz Vif). This suggests that chim-
panzee APOBEC3H and APOBEC3F on their own may not be major species barriers to SIVs
in general, although some SIVs were more efficient than others at antagonizing the chimpanzee
APOBEC3F in particular.
Overall, only the Vif protein from SIVcpz was able to antagonize all tested members of the
chimpanzee APOBEC3 family. The antagonism of SIVcpz Vif corresponds to decreases in the
levels of chimpanzee APOBEC3D, F, G, and H (S4 Fig), consistent with the known mecha-
nisms of Vif-mediated degradation of APOBEC3 proteins [18]. The protein Vif from different
lentiviral lineages had different specificities for a given APOBEC3 substrate (Fig 2D, read the
heat map vertically). For example, chimpanzee APOBEC3G could be antagonized by SIVsmm,
but not by SIVwrc or other SIVs (Fig 2D). Importantly, we also found that a given vif had dif-
ferent specificities amongst the APOBEC3 genes (Fig 2D, read the heat map horizontally).
Indeed, while most of the Vif proteins retained the capacity to antagonize chimpanzee APO-
BEC3F and APOBEC3H, only a few of them were capable to counteract chimpanzee APO-
BEC3D and APOBEC3G (Fig 2D). This suggests that the evolution and retention of multiple
antiviral APOBEC3 proteins in chimpanzees provide a potent restriction to a broad diversity
of lentiviruses, and therefore likely confer an advantage to the species against cross-species
infections. Our data also show that the various SIV lineages have different susceptibility to
chimpanzee restriction factors. For example, SIVsmm strains would be expected to adapt and
antagonize chimpanzee APOBEC3 proteins more readily than strains of SIVwrc, which would
need to adapt to antagonize three APOBEC3 members. Indeed, SIVwrc was unable to cause
degradation of chimpanzee APOBEC3G, F, and D proteins (S4 Fig). Hence, in addition to the
strong barrier conferred by APOBEC3G, other APOBEC3 members, especially APOBEC3D,
also pose an obstacle towards transmission and adaptation of diverse SIVs harbored by mon-
keys to chimpanzees.
Vif-dependent restriction of a lentivirus in primary chimpanzee CD4+ T
cells
We wished to determine if the Vif-dependent restrictions observed in the APOBEC3 over-
expression assays (Figs 1 and 2) could be recapitulated in infections of primary chimpanzee
CD4+ T cells. We modified the proviruses used in Figs 1 and 2 by replacing the HIV-1 env
gene, so that the HIV-1 backbone containing different SIV vif genes would be replication-com-
petent with an X4 envelope from HIV-1. The advantage of this system, as opposed to infection
of chimpanzee cells with different entire SIVs, is that we could control for the other host factors
APOBEC3 as a Barrier to SIV Infection of Chimpanzees
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that may interact in a species-specific manner with the virus, as only the vif gene was different
between the replication-competent viruses. Moreover, certain HIV-1 strains have been shown
to replicate in primary chimpanzee cells [26].
Because of the limiting amounts of primary chimpanzee (Pan troglodytes verus) CD4+ T
cells, we used four HIV-1 clones, each containing a different SIV Vif; two SIV Vifs that fully
antagonized chimpanzee APOBEC3G in the over-expression system (SIVcpz Vif, which served
as a positive control, and SIVsmm Vif), one Vif that partially antagonized chimpanzee APO-
BEC3G (SIVrcm Vif), and one that failed to antagonize chimpanzee APOBEC3G (SIVsab Vif).
An HIV-1 deleted in vif served as a negative control. This assay differs in two important ways
from the single-round assay used in Figs 1 and 2. First, since the viruses are replication-compe-
tent, we measured p24gag production rather than a reporter gene. Second, and more impor-
tantly, viral inocula were initially produced in transfected 293T cells in the absence of any
added APOBEC3 gene. Because APOBEC3G is active in the target cell, rather than the pro-
ducer cell, this means that the first round of infection of the primary cells will proceed uninhib-
ited by APOBEC3G and the effects of endogenous chimpanzee APOBEC3G would be
observed only in the second (and subsequent) rounds of infection.
All viral constructs replicated with comparable kinetics in a “permissive” T cell line, SupT1,
which does not express endogenous APOBEC3G (S5A Fig) [27,28]. This shows that none of
the viral constructs had an inherent replication defect. In primary CD4+ T cells from three
chimpanzee donors, we found that the delta-Vif construct replicated after the initial infection
(as expected since it was produced in cells without APOBEC3G; Fig 3A, grey lines). However,
it did not replicate beyond the first time-point measured (Fig 3A, grey lines). On the other
hand, the construct that encoded an SIVcpz Vif replicated between one to two orders of magni-
tude better than that of the delta-Vif construct (Fig 3A, black versus grey lines). These data
show that the vif gene is essential for efficient viral replication in primary chimpanzee CD4+ T
cells.
We found similar replication patterns in all three chimpanzee CD4+ T cell cultures among
viruses containing different vif genes (Fig 3A). The viral construct containing SIVsab vif repli-
cated to similar levels as the negative control (absence of vif), showing that SIVsab Vif was not
active in chimpanzee cells (Fig 3A, orange line). This result is consistent with the data that SIV-
sab Vif is unable to overcome chimpanzee APOBEC3G (Fig 1B). As control, the infectious pro-
viral construct with SIVsab Vif was fully capable of overcoming AGM APOBEC3G in an
infection assay (S6 Fig). Moreover, these results indicate that of the APOBEC3 proteins, APO-
BEC3G alone is capable of blocking virus replication since SIVsab Vif was able to antagonize
chimpanzee APOBEC3D, F, or H (Fig 2D).
In contrast to viruses encoding SIVsab Vif, viruses that encoded SIVrcm Vif and SIVsmm
Vif had intermediate capacities to replicate in the chimpanzee donor cells (Fig 3A, blue and
green lines). The intermediate replication of the virus encoding SIVrcm Vif (Fig 3A) is consis-
tent with the intermediate ability of SIVrcm Vif to overcome chimpanzee APOBEC3G (Fig
1B). However, the intermediate replication of the virus encoding SIVsmm Vif (Fig 3A) is not
consistent with the full activity of SIVsmm Vif against chimpanzee APOBEC3G (Fig 1B), but
Fig 2. Chimpanzee APOBEC3D, APOBEC3F and APOBEC3H also have antiviral capacities that monkey SIV Vifs differentially antagonize. Single-
round infectivity assay performed in the presence or absence of chimpanzee APOBEC3D (A), APOBEC3F (B), and APOBEC3H (C), as described in Fig 1B.
D, Heat map summarizing the antagonistic potential of Vif from various lentiviruses (shown on the left) against chimpanzee APOBEC3 genes (shown at the
top). The intensity of the color corresponds to the level that a given SIV Vif could antagonize the corresponding chimpanzee APOBEC3 protein (darker is
more antagonism, lighter is less antagonism). The colors were determined according to the infectivity value of the given viral Vif construct relative to the
infectivity of the positive control bearing SIVcpz Vif: lightest green, less than 10% relative infectivity; intermediate green, between 10% and 60% relative
infectivity; dark green, more than 60% relative infectivity.
doi:10.1371/journal.ppat.1005149.g002
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could be explained by the poor activity of SIVsmm Vif against chimpanzee APOBEC3D (Fig
2A and 2D). Therefore, while the Vif-dependent restriction of SIVrcm and SIVsab in primary
chimpanzee CD4+ T cells could be explained by APOBEC3G, the Vif-dependent restriction of
SIVsmmmust be due to another cellular factor, potentially APOBEC3D.
The APOBEC3 proteins are not induced by interferon (IFN) in activated human CD4+ T
cells [27]. However, other Vif-dependent potential restriction factor might be induced by IFN.
Thus, we also performed these experiments in the presence of IFN to determine if we would
see different patterns of virus growth. We found that treatment of primary chimpanzee CD4+
T cells with IFNα or IFNβ lowered the overall amount of lentiviral replication, but did not
change the relative Vif-dependency (Figs 3B and S5B). These data suggest that the non-IFN
induced APOBEC3 proteins are the major Vif targets in activated primary chimpanzee CD4+
T cells.
Fig 3. Vif-dependent restriction of lentiviral replication in primary chimpanzee CD4+ T cells. A, Primary CD4+ T cells from three chimpanzee donors
were infected with replication-competent HIV-1 clones containing either no Vif (ΔVif) or Vif from different SIV lineages (SIVcpz, SIVsab, SIVrcm, or SIVsmm)
as described in the methods. Viral replication was evaluated by measuring HIV p24 titers every 48h over a 9- or 10-day course of infection. B, The same
experiment was performed, but cells were treated with 500 U/ml of IFNα (left) and 100 U/ml of IFNβ (right) 24h prior infection (data are shown here for cells
from donor 1; data for donor 2 are shown in S5B Fig).
doi:10.1371/journal.ppat.1005149.g003
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The APOBEC3 proteins mediate their antiviral effects through the hypermutation of the
newly synthesized viral genome by their cytidine deaminase activity, as well as other proposed
mechanisms [19,29]. As one of the hallmarks of the APOBEC3 restriction is the induction of
G-to-A hypermutation in viruses (reviewed in [18]), we looked for evidence of such hypermu-
tation in integrated viral genomes nine days after infection of primary chimpanzee CD4+ T
cells. Genomic DNA was extracted from infected cells and two fragments (of ~1,200 bp and of
~600 bp) encompassing the vif region were amplified, cloned, and sequenced (see Methods).
Two methods were used to determine the significance of hypermutation signatures, Hypermut
[30] and Hyperfreq [31], which both determine that a sequence is hypermutated when G-to-A
mutations in a given hypermutation-associated context are more likely than mutations in a
control context. The first method uses the Fisher exact test, while the second one uses a Bayes-
ian approach and can evaluate the strength of various hypermutation contexts [31] (see
Methods).
We found that the viral construct that lacked a vif gene accumulated many G-to-A muta-
tions in its genome (G-to-A mutation rate of 0.65%, versus 0.05% for other mutations; Table 2,
ΔVif column) and 50% of the sequences were found to be significantly hypermutated in an
APOBEC3-context (p<0.05) (Table 2). These mutations occurred primarily in the GG context,
which is characteristic of APOBEC3G activity (85% of the mutations were in the GG context
and, using Hyperfreq, hypermutation of sequences was most frequently associated with the GG
context, Table 2). However, G-to-A mutations also occurred in the GA context, which may be
a signature of APOBEC3F, APOBEC3D, and/or APOBEC3H activity (Table 2) [25,32]. In con-
trast, the viral construct that expressed the SIVcpz Vif had no evidence of hypermutation
(Table 2, cpzVif column). This suggests that the expression of the APOBEC3 proteins in acti-
vated primary chimpanzee CD4+ T cells was able to hypermutate the viral genome in the
absence of Vif antagonism, with APOBEC3G being the main driver, and that SIVcpz Vif could
counteract this APOBEC3-mediated hypermutation.
Table 2. G-to-A hypermutation signatures in viral genomes after nine days of infection in chimpanzee primary CD4+ T cells are dependent on Vif.
Primary CD4+ T cells from the chimpanzee donor 1 were infected with replication competent viruses HIV:ΔVif, sabVif, rcmVif, smmVif, or cpzVif. Cells were
harvested after nine days of infection and genomic DNA was extracted. Viral fragments and clones were retrieved as described in the methods. Sequences
were analyzed for G-to-A (“G>A”) hypermutation significance using Hypermut [30] and Hyperfreq [31], as described in the methods.
ΔVif sabVif rcmVif smmVif cpzVif
Sequenced clones 16 9 21 25 21
Total bp sequenced 9169 7688 21446 27577 23891
G>A in GG contexta 51 62 2 1 0
G>A in GA context 8 0 6 1 1
Total number of G>A 60 62 10 2 1
G>A mutation rate (%) 0.65 0.81 0.05 0.01 0.00
Intact Vif ORFb NA 2/9 all all all
Hypermut: Hypermutant clones p<0.05c 6/16 6/9 0/21 0/25 0/21
Hyperfreq: Hypermutant clonesd (strongest pattern)e 8/16 (7 GG, 1 GR) 6/9 (6 GG) 2/21 (2 GA) 0/25 0/21
Other mutations 5 5 14 13 15
Other mutation rate (%) 0.05 0.07 0.07 0.05 0.06
a, number of G-to-A mutations in the GG context
b, number of intact Vif open reading frame (ORF), NA, not applicable
c, Number of clones that are significantly considered as hypermutant (p<0.05) using Hypermut 2.0 [30]
d, Number of clones that that were considered as positive for hypermutation at the significance level of 0.05 [31]
e, Strongest pattern, pattern in which the evidence of hypermutation appeared to be the strongest [31].
doi:10.1371/journal.ppat.1005149.t002
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In the virus construct that encoded SIVsab Vif, we found an elevated G-to-A mutation rate
in the GG context (0.81%, versus 0.07% for other mutations, Table 2) and 67% of the sequences
were found to be significantly hypermutated in the APOBEC3G-context (p<0.05 with both
Hypermut and Hyperfreq, Table 2). Importantly, seven recovered viral clones out of nine har-
bored premature stop codons in the sequenced open reading frames. Therefore, the accumula-
tion of G-to-A mutations mediated by APOBEC3G may be directly responsible for the poor
viral growth of viruses encoding SIVsab Vif in primary chimpanzee CD4+ T cells (Fig 3).
By analyzing the viruses encoding SIVrcm Vif and SIVsmm Vif, we did not find any evi-
dence of APOBEC3G deaminase activity (Table 2). However, for the virus encoding SIVrcm
Vif, two viral clones out of 21 were significantly hypermutated in the GA context (p<0.05
Hyperfreq, Table 2), suggesting that APOBEC3D, APOBEC3F, and/or APOBEC3H were active
against this virus. This is consistent with our single-round infectivity results where SIVrcm Vif
could not antagonize chimpanzee APOBEC3D (Fig 2A and 2D). The little or lack of hypermu-
tation observed in the viral constructs containing SIVsmm vif or SIVrcm vif, for which replica-
tion was only partly inhibited, may be due to the fact that the mutational activity of the
APOBEC3 family members was below our limit of detection at nine days post infection (e.g.
due to outgrowth of a subpopulation of virus that escaped hypermutation or other causes). On
the other hand, the low hypermutation rate may also suggest that a Vif-dependent host factor
that does not rely on its deaminase activity was in part responsible for this phenotype.
Chimpanzee and bonobo populations harbor genetic variants of the
APOBEC3 genes, but all are similarly active and resistant to lentiviral Vif
antagonism
Polymorphisms in APOBEC3 genes from various primates may impact protein function or the
capacity to escape from viral antagonists [16,17,33]. Therefore, we sought to identify and func-
tionally characterize genetic variants of the APOBEC3 genes present in bonobos (Pan paniscus)
as well as different subspecies of common chimpanzees (Pan troglodytes). To date, the sequence
of the APOBEC3 genes has only been reported from bonobos and western chimpanzees (P. t.
verus)—two populations that appear currently free of lentiviral infection [1,5] (Fig 4A). Here,
we analyzed the deep-sequencing reads from the Great Ape Genome Project [34] to determine
whether additional polymorphisms existed in the non-human hominoid APOBEC3 sequences,
in particular between chimpanzee subspecies that harbor SIVcpz and those that do not. Specifi-
cally, we mapped reads to the chimpanzee reference genome (panTro3) using BWA-MEM
aligner, which allowed us to appropriately retrieve the polymorphisms for the APOBEC3 gene
family. We also performed Sanger sequencing on a subset of 16 variants and validated the poly-
morphisms and the heterozygous/homozygous sites for all the variants tested (S7 Fig). Overall,
we recovered genetic variants for APOBEC3D, G, F, and H genes, from a total of 36 individuals
including five western chimpanzees, ten Nigerian-Cameroonian chimpanzees, four central
chimpanzees, six eastern chimpanzees, and eleven bonobos (Fig 4A).
In the coding regions of the APOBEC3 genes, we found multiple sites that were polymorphic
within and/or between chimpanzee populations (Table 3). The majority (56%) of the individu-
als were homozygous for the reference nucleotide at polymorphic sites, 31% were homozygous
for the alternate nucleotide, while 12% were heterozygous. None of the variants were found in
the cytidine deaminase domains. The APOBEC3G and APOBEC3F genes had the greatest num-
ber of polymorphic sites, and five out of eight SNPs in each gene coded for amino acid changes
(Table 3). In addition, none of the SNPs identified in chimpanzees were overlapping with the
common polymorphisms (MAF>1%) that have been described in human APOBEC3 genes
[35].
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To determine whether or not the identified APOBEC3 genetic variants impacted their anti-
lentiviral function and/or their escape from Vif antagonists, we tested the effect of a subset of
SNPs that were in, or proximal to, putative Vif binding regions (Table 3, underlined positions).
In particular, we tested one SNP in APOBEC3D (N324D) and two SNPs in APOBEC3F
(E282D and S322R), all of which were found in regions known to affect HIV Vif binding [36],
as well as all five non-synonymous SNPs in APOBEC3G (Table 3). We found that all variants
had similar levels of expression in transient expression assays (Fig 4B), and all retained their
antiviral capacity in the absence of Vif (Fig 4C,—Vif). We also tested the APOBEC3 variants
against a panel of Vif from three SIVs that have different antagonist specificities and are from
different primate species: SIVcpz from chimpanzees, SIVwrc from western-red colobus, which
Fig 4. The chimpanzee and bonobo populations are uniformly resistant to lentiviruses with various Vifs. A, Graphical representation of Pan species
and subspecies phylogeny (top) and geographic ranges (bottom) with the number of individuals per (sub)species that were examined for their APOBEC3
genes (in red, before the study; in black, in this study). The virus diagrams depict the two chimpanzee subspecies known to be infected by SIVcpz. B,
Expression of transient chimpanzee APOBEC3D, APOBEC3F, and APOBEC3G variants. Western-blot analyses against HA-tagged APOBEC3 proteins.
Tubulin serves as a loading control. C, Chimpanzee APOBEC3D, APOBEC3F, and APOBEC3G variants have comparable activity against lentiviruses and
are antagonized similarly by primate lentiviral Vifs. Single-round infectivity assays, as described in Fig 1B, in the presence or absence of chimpanzee
APOBEC3 variants with HIVΔVifΔEnvLuc2: ΔVif, SIVcpz Vif, SIVsmm Vif, or SIVwrc Vif. Infectivity in the absence of APOBEC3 was normalized to 100%.
APOBEC3D variants are in purple, APOBEC3F variants are in blue, and APOBEC3G variants are in green.
doi:10.1371/journal.ppat.1005149.g004
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is chimpanzee’s main monkey prey, and SIVsmm from sooty mangabeys (Fig 2D). Although
SIVcpz infects only two chimpanzee subspecies, we found that SIVcpz Vif could antagonize all
chimpanzee APOBEC3 variants tested (Fig 4C). Furthermore, the APOBEC3D, APOBEC3F,
and APOBEC3G genetic variants, despite harboring variations in the potential Vif binding
pocket, did not affect the antagonist capacity of SIV Vifs (Fig 4C). Although some variation in
the ability of SIVwrc Vif to counteract APOBEC3G genetic variants was observed, SIVwrc Vif
was not able to the rescue viral infection in any condition. Thus, our conclusions on chimpan-
zee APOBEC3 resistance against lentiviruses from monkeys that were made from the sequence
of APOBEC3 genes from a single P. t. verus individual (Figs 1 and 2) and on primary cells from
three P. t. verus donors (Fig 3) are representative of all the chimpanzee and bonobo popula-
tions. Therefore, the APOBEC3 genes may uniformly protect chimpanzees and bonobos
against the emergence of most primate lentiviral lineages.
Table 3. Genetic variations in APOBEC3 genes between and within chimpanzee (sub)species. Single nucleotide variants found in coding regions of
the four antiviral APOBEC3 genes of the Pan genus. The variants that were tested in functional assays are underlined.
POSITIONa GENE POS. NTb REF ALT POS. AAc REF ALT Summary of ALTd HOM REFe HETf HOM ALTg
chr22 37702355 A3D 41 G T 14 R L 2 Pts 34 1 1
37705109 536 A C 179 Q P 5 Pte, all Pts, 3 Ptt 22 5 9
37711387 957 G C 319 L = 23 4 9
37711400 970 A G 324 N D all Pp, 2 Pts 23 3 10
37711810 1156 C G 386 Q E 2 Pts 34 2 0
chr22 37722398 A3F 79 A C 27 I L All Pp, 8 Pte, all Pts, all Ptt 6 3 27
37724331 179 T A 60 F Y 5 Pte, 2 Pts, 1 Ptt, 1 Ptv 26 8 2
37724599 447 T C 149 D = 31 3 2
37728898 657 C T 219 C = 31 3 2
37731538 846 G C 282 E D 8 Pp 28 5 3
37731658 966 T G 322 S R 7 Pp, 6 Pte, 3 Pts 20 12 4
37732031 1116 C T 372 L = 25 9 2
37732032 1117 G C 373 E Q 4 Pp, 7 Pte, 1 Pts 24 8 4
chr22 37754866 A3G 86 A G 29 H R All Pp, Pte, Pts, and Ptt 5 0 31
37759663 644 G A 215 R Q All Pte, 5 Pts, all Ptt 17 6 13
37759713 694 T C 232 W R All Pp, all Pte, 5 Pts, all Ptt 6 5 25
37759743 724 T C 242 L = 0 0 36
37762166 737 C A 246 A D 6 Pp 30 6 0
37762180 751 G A 251 G S 3 Pts 33 3 0
37762188 759 T C 253 L = 27 6 3
37762371 942 A C 314 I = 0 0 36
37762374 945 G T 315 * Y all 0 0 36
chr22 37777860 A3H 481 A G 161 K E 5 Pte, 5 Pts, all Ptt 22 10 4
a, position of the variant on the chimpanzee reference genome panTro3; chr22, chromosome 22.
b, position of the nucleotide variant within the gene; REF, nucleotide found on panTro3 reference genome; ALT, variant; equal sign, synonymous change.
c, position of the corresponding amino acid within the protein. Underlined SNPs were functionally tested (Fig 4).
d, summary of the individuals bearing the variant; Pp, Pan paniscus; Pts, Pan troglodytes schweinfurthii; Ptt, P. t. troglodytes; Pte, P. t. ellioti; Ptv, P. t.
verus.
e, total number of individuals homozygous for the reference.
f, total number of individuals heterozygous.
g, total number of individuals homozygous for the variant.
doi:10.1371/journal.ppat.1005149.t003
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Discussion
Although chimpanzees are frequently exposed to various lentiviruses that infect their monkey
preys, they harbor only one SIV, SIVcpz. The fact that chimpanzees have remained resistant to
other SIVs is especially intriguing because they have acquired other retroviruses from monkeys
(reviewed in [1,6]). Here, we show that the APOBEC3 family of antiviral proteins may repre-
sent a powerful barrier against cross-species infection of most SIVs to chimpanzees. We found
that chimpanzee APOBEC3G blocks viral replication of most SIV strains to which these apes
are exposed [6–9]. Furthermore, our data are consistent with the hypothesis that encoding
multiple APOBEC3s with different virus-host interfaces contributes to the protection of a host
against cross-species transmission by being differentially resistant to the vif antagonist encoded
by monkey lentiviruses. Moreover, the Vif-dependent lentiviral replication observed in pri-
mary chimpanzee cells, which varied according to the SIV of origin, highlights the importance
of Vif in the spread of lentiviruses between species. Finally, although polymorphisms in the
APOBEC3 genes are found across chimpanzee populations, we found that the different (sub)
species (regardless of whether or not they currently harbor SIVcpz in their population) encode
APOBEC3 proteins with similar specificity. We would therefore expect the common chimpan-
zee and bonobo populations to be similarly resistant to the Vif antagonism from most SIVs.
The potential for APOBEC3G to act as a species barrier to lentiviral
emergence in chimpanzees
We found that chimpanzee APOBEC3G cannot be fully antagonized by the Vif protein of any
circulating monkey SIV, except by Vif from the SIV infecting sooty mangabeys. Therefore,
with the caveat that our experiments were done in vitro, and therefore are much more simpli-
fied than what occurs in actual transmissions in the wild, these results are consistent with the
hypothesis that APOBEC3G in chimpanzees is a host factor that represents a potent species
barrier to very diverse primate lentiviruses. This factor alone could explain why SIVwrc from
western-red colobus has not crossed into chimpanzees despite ample evidence of exposure of
chimpanzees to this virus in their prey [6,7]. This result is consistent with other reports on
APOBEC3G as a selective barrier to heterologous viruses [14–17]. Moreover, our previous
studies found that a dramatic change in the vif gene at the “birth” of SIVcpz was needed to
allow vif adaptation to chimpanzee APOBEC3G [4]. Finally, Vif-APOBEC3G antagonism in
natural host switches (Table 1 and S2 Fig) suggests that at least partial antagonism of APO-
BEC3G may be a pre-requisite to natural cross-species infection.
In primary chimpanzee CD4+ T cells, we observed a strong replication defect of lentiviruses
with heterologous Vifs that cannot antagonize chimpanzee APOBEC3G, as shown with a viral
construct bearing SIVsab Vif. Indeed, this construct accumulated numerous mutations in the
GG context including stop codons that would be deleterious for the virus. Therefore, it is likely
that APOBEC3G would not allow for sufficient rounds of replication of viruses that harbor a
non-active Vif (such as SIVsab, SIVwrc and many others) for adaptation to chimpanzee.
While several other restriction factors may play a role as species barrier in different settings,
their role in protection of chimpanzees against cross-species infection of SIVs is far less com-
pelling than that of the APOBEC3 family. For example, TRIM5 is also known to be a species
barrier in experimental transmissions of HIV-1 to rhesus macaques [14,15]. However, none of
a diverse panel of SIVs tested were sensitive to the restriction by chimpanzee TRIM5 [37]. In
addition, the restriction imposed by the antiviral gene Tetherin/BST-2 is less likely to block
cross-species transmissions since many SIVs may have a Nef protein capable of antagonizing
chimpanzee Tetherin/BST-2, which, in contrast to human has a cytoplasmic terminal domain
similar to other monkeys [38]. However, our results do not rule out that additional barriers to
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SIV infections of chimpanzees (for example, receptor or co-receptor mismatches, and other
possible antiviral genes) might also exist.
The role of APOBEC3 gene family evolution and variability in preventing
SIV cross-species transmission
The duplication and subsequent evolution of the APOBEC3 genes in primates may be an effi-
cient evolutionary strategy for the host to keep up in the virus-host arms race. This evolution-
ary strategy may generally be beneficial to target several viruses [39,40], as well as to target a
single rapidly evolving virus that will need to develop multiple defense strategies. Here, the fact
that a single antagonist, Vif, targets the various host APOBEC3 proteins may be an efficient
strategy for the host to provide a broad spectrum of defense against a potential emerging virus.
Moreover, although APOBEC3G exert the main lentiviral restriction amongst the APOBEC3
members, it was shown that human APOBEC3D, APOBEC3F, and APOBEC3H also restrict
lentiviruses in primary cells and in humanized mice [27,28,41]. The caveat to this conclusion
to in vivo transmission is that we do not yet know the expression of the different chimpanzee
APOBEC3 proteins in the SIV target cells. Nonetheless, as the mRNAs corresponding to the
human versions of the APOBEC3 proteins are widely expressed [27], it is likely that the single
viral protein Vif would need to simultaneously adapt to multiple host restriction factors with
different interfaces to allow viral replication in chimpanzees. Furthermore, Vif has distinct
regions for antagonizing the APOBEC3 proteins [19,42,43]. Therefore, overcoming one APO-
BEC3 protein after adaptation will not necessarily allow the virus to overcome the other APO-
BEC3 members. In heterologous SIV infections of AGMs, viral adaptation was impaired when
Vif had to adapt to two alleles of APOBEC3G, highlighting the role of “heterozygous advan-
tage” [17]. The host advantage of multiple alleles can be extended to the harboring of multiple
antiviral genes from the same family. Therefore, when a Vif protein needs to adapt to multiple
APOBEC3 members, as SIVwrc Vif in chimpanzees, it would increase the host advantage and
drastically constrain viral evolution and adaptation to the new species.
Vif-dependent restriction of SIVsmm in chimpanzees
SIVsmm from sooty mangabeys has been able to cross multiple times to humans giving rise to
HIV-2 viruses. Two independent SIVsmm transmissions were successful and are at the origin
of the HIV-2 epidemic in West Africa, while at least seven others have been found in only few
individuals with no or very limited secondary spread [44,45]. In contrast, no equivalent
SIVsmm emergence in chimpanzees has been recorded. The present-day lack of transmission
of SIVsmm into chimpanzees is most likely due to ecological factors since, amongst chimpan-
zees and bonobos, only western chimpanzees have overlapping ranges with sooty mangabeys
and they do not frequently hunt sooty mangabeys [6]. Nonetheless, as SIV infection of mon-
keys has been ongoing for millions of year [20,46,47], we believe that it is likely that at some
time in the past chimpanzees would have been exposed to an SIV with a vif gene with a similar
specificity as modern-day SIVsmm. Our results on infections in primary chimpanzee CD4+ T
cells show that there is a clear Vif-dependence of infection, where the SIVsmm Vif poorly sup-
ports viral replication in these cells. We found that this impairment cannot be explained by
restriction by APOBEC3G, APOBEC3F, or APOBEC3H (Fig 2D, SIVsmm Vif). However,
because chimpanzee APOBEC3D has stronger antiviral activity compared to human APO-
BEC3D ([25] and S3 Fig) and SIVsmm Vif is not able to fully antagonize chimpanzee APO-
BEC3D (Fig 2A), it is possible that this host protein may be responsible for the reduced
infection of the virus with SIVsmm vif in primary chimpanzee cells (Fig 3). Notably, at least in
human cells, APOBEC3D, is expressed in primary CD4+ T cells and can have antiviral effects
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[27,28,41]. Moreover, major evolutionary changes in Vif were necessary for adaptation of
SIVcpz to chimpanzees, which included adaptation to chimpanzee APOBEC3D [4]. On the
other hand, human APOBEC3D was unlikely a barrier to transmission of SIVsmm to humans
[25].
In a nine-day infection of primary chimpanzee CD4+ T cells, we did not observe any signa-
ture of APOBEC3D deaminase activity in the presence of SIVsmm Vif. It is possible that this
activity is not observed in our system, but can have some impact in vivo, or that it acts primar-
ily by a deaminase-independent mechanism [29]. It is also possible that another Vif-dependent
factor is responsible for the viral growth defect in chimpanzee cells.
Selection for the protection of hominoids to most SIVs?
Screening for variants in the APOBEC3 genes among the chimpanzee population, we found
that these host proteins are polymorphic, but that functionally they are all similarly resistant or
susceptible to circulating lentiviruses. This is similar to what has been described for the com-
mon polymorphisms found in APOBEC3 genes in different human populations [35]. Although
only two subspecies of chimpanzees are infected by SIVs, these do not harbor functionally dif-
ferent APOBEC3 genes from the ones found in bonobos or western chimpanzees that appear
free of lentiviral infection [5,7]. This emphasizes that even though this gene family is polymor-
phic in common chimpanzees and bonobos, these modern-day apes are similarly resistant to
Vif from diverse SIVs across Africa. These findings are however in contrast to studies on APO-
BEC3G from captive macaques, APOBEC3G from wild African green monkeys, or human
APOBEC3H, where polymorphisms influence the host protein restriction capacity or suscepti-
bility to Vif [16,17,33,48]. This suggests that the main antiviral APOBEC3 genes in chimpan-
zees may have been under strong selection either now or in the recent past to prevent invasion
by other primate lentiviruses. On the other hand, the recent introduction and low overall prev-
alence of SIVcpz relative to lentiviruses of other primates [5,46,49] may also explain why we do
not observe an ongoing “arms race” between chimpanzee APOBEC3 genes and the SIV vif gene
as observed in other primate species [17].
Both common chimpanzees and bonobos harbor multiple APOBEC3 gene members that
are strongly active against lentiviruses, including APOBEC3D and APOBEC3H that otherwise
have a poor anti-lentiviral capacity in humans [25,33]. Together with our population genetic
data, the strong positive selection observed in hominoids’ APOBEC3 genes [25,33,50,51] sug-
gests that ancient lentiviruses had infected primates before the split between common chim-
panzees and bonobos, and thereafter shaped their host genomes by selection. Indeed, selection
in the APOBEC3D gene for its increased activity against lentiviruses occurred at the chimpan-
zee/bonobo common ancestor [25]. It is tempting to speculate infection by a virus similar to
SIVsmmmight have driven this selection. An ancient selective event is further supported by
the evidence of a selective sweep of the MHC class I repertoire in chimpanzees [52]. Therefore,
the antiviral defenses of the APOBEC3 locus of modern-day chimpanzees and bonobos may
have been shaped by ancient lentiviruses and have recently been under continued selection,
such that now they are particularly resistant to most SIV cross-species transmissions.
Methods
Plasmids
Expression plasmids for chimpanzee APOBEC3 genes were previously described; briefly, chim-
panzee APOBEC3D was cloned into pCS2+ with a 3’end HA epitope tag [25] and chimpanzee
APOBEC3G, APOBEC3H, and APOBEC3F were cloned into pcDNA3.1 vector with a 5’end
HA epitope tag [4,33]. All these APOBEC3 genes are from the Pan troglodytes verus
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chimpanzee subspecies. APOBEC3 mutants bearing the newly identified SNPs (Fig 4) were
made by site-directed mutagenesis of the APOBEC3 plasmids (Quick Change II Site Directed
Mutagenesis Kit, Agilent Technologies).
Recombinant HIV-1ΔVifΔEnvLuc2 proviral plasmids encoding vif from SIVsmm E041,
SIVwrc 98CI04, SIVolc 97CI12, SIVmus-1 CM1085, SIVdeb CM5 were previously described
[20], the ones with vif from SIVagm.sab-1, SIVagm.ver-90, SIVagm.gri-667, SIVagm.tan-1 are
from Compton et al. 2012 [17], the ones with vif from SIVrcm CM8081, SIVcpzPts TAN3,
SIVcpzPts UG38, SIVcpzPts TAN13, SIVcpzPtt Gab1, SIVcpzPttMB66 are from Etienne et al.
2013 [4], and the ones with vif from SIVcpzPts BF1167, SIVcpzPtt EK505, and SIVcpzPtt
DP943 are from this study. All were cloned as previously described [4]. The various Vifs are
expressed at similar expression levels and have the capacity to fully antagonize at least one
APOBEC3 protein [4,17,20].
For the spreading infections, replication-competent recombinant HIV-1 proviral plasmids
encoding vif from SIVsmm E041, SIVagm.sab-1 (named SIVsab), SIVcpzPts TAN3, and
SIVrcm CM8081 were cloned into an HIV-1 backbone in place of the HIV-1 vif and all harbor
an intact env gene.
Single-round viral infectivity assays and western-blot analyses
293T cells (obtained from the American Type Culture Collection (ATCC)) were co-transfected
with 400 ng of APOBEC3 plasmid or an empty expression vector, 600 ng of proviral HIV-1
plasmid (HIV-1ΔVifΔEnvLuc2) with an SIV vif, and 200 ng of L-VSV-G for pseudotyping,
using TransIT-LT1 (Mirus Bio). The cells and the virus supernatant were collected 48–72h
post transfection. The harvested cells were used for the western-blot analyses and the following
antibodies were used: mouse HA-specific antibody (Balco), mouse anti-tubulin and anti-actin
antibodies (Sigma-Aldrich), and secondary goat anti-mouse horseradish peroxidase-conju-
gated antibody (Sigma-Aldrich). The total amount of virus in the supernatant was quantified
by p24 Gag ELISA assay (Advanced Bioscience Laboratories). Each transfection condition was
performed in 2–3 independent experiments. For the infection, SupT1 cells (obtained from the
NIH AIDS Repository) were plated at 0.4 M cells/ml with 20 μg/ml of diethylminoethyl-dex-
tran and infected with 2 ng of virus. Infections were performed in triplicate and luciferase activ-
ity was measured after 72h with the Bright-Glo Luciferase Assay Reagent (Promega).
Generation of replication-competent viral stocks
293T cells were transfected with 1,200 ng of replication-competent proviral HIV-1 plasmids
with an SIV vif using TransIT-LT1 (Mirus Bio). The virus supernatants were collected 48–72h
post transfection. The total amount of virus in the supernatant was quantified by p24 Gag
ELISA assay (Advanced Bioscience Laboratories) or p24 Gag AlphaLISA assay (Perkin Elmer).
Infections of primary chimpanzee CD4+ T cells and SupT1 “permissive”
cell line
Leftover blood samples from health examinations of uninfected chimpanzees housed at the
Yerkes Regional Primate Center were shipped at room temperature and peripheral blood
mononuclear cells (PBMCs) were isolated by gradient centrifugation using Ficoll-Paque Plus
(GE Healthcase Life Sciences). These chimpanzee PBMCs were enriched for CD4+ T cells
using non-human primate CD4 MicroBeads (MACS Miltenyi Biotec) and magnetic cell sorting
(Militenyi Biotec), stimulated with staphylococcal enterotoxin B (Sigma-Aldridge) for 12 to 15
hours (3 μg/ml), and subsequently co-cultivated with autologous monocyte-derived macro-
phages for optimal activation as described [26]. 250 ng of each viral construct were used to
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infect 106 activated primary chimpanzee CD4+ T cells [26]. After 12h, cells were washed four
times with PBS and were resuspended in new media. 50 μl of supernatant were collected every
48h up to 9–10 days post-infection. The total amount of virus at each time point was measured
using the p24 Gag PE AlphaLISA assay. The experiment was performed using primary CD4+ T
cells from three different chimpanzee donors also obtained from the Yerkes Primate Center.
For the replication experiments in the presence of IFN, activated chimpanzee CD4+ T cells
were pretreated for 24h with 500 U/ml of human IFN-alpha2 or 100 U/ml of human IFN-beta
prior to infection. Each IFN was replenished every 48h throughout the replication kinetic. The
experiment in the presence of IFN was performed using primary CD4+ T cells from two chim-
panzee donors.
Human SupT1 cells were infected with 2 ng of each viral construct, using 20 μg/ml of
diethylminoethyl-dextran, and spinoculated for 2h at 1,600 rpm. After 12h, cells were washed
four times with PBS and were resuspended in new media. 50 μl of supernatant were collected
every 48h up to nine days post infection. The total amount of virus at each time point was mea-
sured using ABL p24 Gag ELISA assay.
G-to-A hypermutation analyses
Primary chimpanzee CD4+ T cells from the donor 1 were harvested nine days post infection.
Total DNA was extracted using the QIAamp DNA mini kit (QIAGEN). Two fragments were
amplified using the AccuPrime Taq DNA polymerase (Invitrogen) with 40 cycles of amplifica-
tions. One small fragment encompassed the vif gene and was of approximately 600 bp (size
depends on amplified SIV vif; primers are as followed Primer-vif-F, 5’-CAG CAA AGC TCC
TCT GGA AAG GT-3’, and Primer-vif-R, 5’-CTA TGT CGA CAC CCA ATT CTG AAA TG-
3’). A second fragment that starts in the pol gene and finishes in the vpr gene was of approxi-
mately 1,200 bp, and primers Primer-pol-F, 5’-GAA TTT GGA ATT CCC TAC AAT CCC C-
3’, and Primer-vpr-R, 5’-CTA CTG GCT CCA TTT CTT GCT CTC C-3’, were used for ampli-
fication. Amplicons were gel purified and cloned using the TOPO TA cloning system (Invitro-
gen). Between nine and 25 clones were sequenced per sample and the total number of
nucleotides analyzed per sample were 7,688–27,577 bp, as shown in Table 2. The hypermuta-
tion significance was calculated using two methods. First, we used Hypermut 2.0, which deter-
mines if the mutations in a given G-to-A context exceed the mutations out of context using a
Fisher test, with a threshold of p<0.05 [30]. Second, we used Hyperfreq, which estimates the
relative probability of G-to-A mutation in a given context versus a control context using a
Bayesian approach [31]. The advantage of this second method is that it also evaluates the
“strength” of various hypermutation contexts [31]. Here, we ran the Hyperfreq analyses using
a level of significance of 0.05 in three different contexts: a GG context (consistent with primar-
ily APOBEC3G activity), a GA context (consistent with primarily APOBEC3F and/or APO-
BEC3D activities), and a GR context (consistent with a combined activity of APOBEC3G and
APOBEC3F and/or APOBEC3D).
Deep-sequencing analyses of the Pan APOBEC3 genes
In order to assess the diversity of the APOBEC3 gene family amongst wild chimpanzee and
bonobo populations, we leveraged full-genome shotgun sequencing data of 25 common chim-
panzees and 11 bonobos sequenced as part of the Great Ape Genome Sequencing Project [34].
Representatives from each of the four recognized common chimpanzee subspecies were
included, five western chimpanzees, ten Nigerian-Cameroonian chimpanzees, four central
chimpanzees, and six eastern chimpanzees. The raw reads for all chimpanzee and bonobo indi-
viduals were mapped to the complete chimpanzee reference genome PanTro3 using
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BWA-MEM (arXiv:1303.3997v2 [q-bio.GN]) with default parameters. SNPs were called using
Samtools and default parameters with all individuals combined during the calling step [53].
Sanger sequencing of the APOBEC3 genes
We confirmed the deep-sequencing results of a subset of polymorphic sites (n = 16) in the
chimpanzee APOBEC3 genes by Sanger sequencing. PCRs were performed from total genomic
DNA (a kind gift from Evan Eichler [34]), using APOBEC3 primers (for APOBEC3G: F, 5’-
TTT GGA GGC TCT AGC AAG TGA GTG-3’ and R, 5’- AGC TAC AGG AAG CAC AGG
TGA-3’; for APOBEC3D: F, 5’- CCT GCC CTC TTC TCC CAT CG-3’ and R, 5’- CGT AGC
ATT GTT TTC AGA AGT CG-3’; for APOBEC3F: F, 5’- TCC GCC CTC TGC TCT CAT C-3’
and R, 5’- CTG CAG CTT GCT GTC CAG GAA TAG-3’) and Accuprime Pfx DNA polymer-
ase (Invitrogen). After gel purification, all the amplicons were sequenced and the SNPs were
confirmed in all cases, including heterozygous and homozygous sites (S7 Fig).
Phylogenetic analyses of lentiviral Vif
The sequences of Vif from the SIV lineages were obtained from the Los Alamos HIV sequence
database (http://www.hiv.lanl.gov/). The amino acid sequences were aligned using FSA [54]
and the phylogenetic analyses were performed using PhyML with a JTT model [55].
Supporting Information
S1 Fig. Chimpanzee APOBEC3 protein expression and antagonism by Vif from various
SIVcpz strains. A, Western-blot analysis against HA-tagged APOBEC3G, APOBEC3D, APO-
BEC3F, APOBEC3H from chimpanzee. Tubulin serves as a loading control. B, Vif from diverse
SIVcpz strains antagonizes chimpanzee APOBEC3G. Single-round infectivity assays were per-
formed as described in Fig 1B in the presence or absence of chimpanzee APOBEC3G and with
HIVΔVifΔEnvLuc2 plasmid with inserted Vif from various SIVcpz strains: four SIVcpzPtt
strains (red tones) and four SIVcpzPts strains (blue tones). The reference of each strain tested
is shown in the figure.
(TIF)
S2 Fig. SIVagm viruses that crossed to baboon and patas monkeys in the wild have an active
Vif against the APOBEC3G of the new host species. Single-round infectivity assays were per-
formed as described in Fig 1B. Left panel, Infection in the presence or absence of vervet APO-
BEC3G or baboon APOBEC3G with HIVΔVifΔEnvLuc2 plasmid (white) or the plasmid with
inserted SIVver vif (black). Right panel, Infection in the presence or absence of sabaeus APO-
BEC3G or patas APOBEC3G with HIVΔVifΔEnvLuc2 plasmid (white) or the plasmid with
inserted SIVsab vif (black).
(TIF)
S3 Fig. Chimpanzee APOBEC3D is more active against lentiviruses than human APO-
BEC3D. A, Single-round infectivity assay was performed as described in Fig 1B with HIVΔVif-
ΔEnvLuc2 plasmid (no Vif) in the absence or presence of an increasing dose (0–400 ng) of
chimpanzee or human APOBEC3D. B, Western-blot analysis against HA-tagged APOBEC3D
from chimpanzee and human. Actin serves as a loading control. Normalized ratio of HA-A3D
expression over actin are shown. This is a representative experiment of three repeats.
(TIF)
S4 Fig. SIVcpz Vif, but not SIVwrc Vif, decreases intracellular levels of all chimpanzee
APOBEC3 proteins. HA-tagged versions of chimpanzee APOBEC3G, APOBEC3D,
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APOBEC3F, and APOBEC3H were transfected into 293T cells along with a proviral construct
with no Vif (-), SIVcpz Vif (cpz), or SIVwrc Vif (wrc). Two days after transfection, cell extracts
were collected, ran on SDS-PAGE gels, and probed with an antibody against HA (to detect
APOBEC3 proteins) and an antibody against actin (as a loading control). SIVcpz Vif decreases
the levels of chimpanzee APOBEC3G (on the left), and chimpanzee APOBEC3D, chimpanzee
APOBEC3F, and chimpanzee APOBEC3H (on the right). SIVwrc Vif did not affect levels of
the chimpanzee APOBEC3G, D, and F proteins relative to blots with no Vif. There was a small
decrease of chimpanzee APOBEC3H level in the presence of SIVwrc Vif, in accordance with
our infectivity data (Fig 2). M, Molecular weight marker. The arrows point to the actin band on
the top and to the different sizes of APOBEC3G, D, F, and H.
(TIF)
S5 Fig. Replication of lentiviral Vif constructs in control SupT1 cells (A) and IFN-treated
chimpanzee primary CD4+ T cells (B). A, Human SupT1 “permissive” cell line [27,28] was
infected with replication-competent clones of HIV-1 encoding either no vif (ΔVif) or vif from
different SIV lineages (SIVcpz, SIVsab, SIVrcm, SIVsmm). Viral replication was evaluated by
measuring HIV p24 titers every 48h over a 9-day course of infection. B. Primary CD4+ T cells
from the chimpanzee donor 2 (data from donor 1 are in Fig 3B) were treated for 24h with 500
U/ml of IFNα (left) and 100 U/ml of IFNβ (right) and infected with replication-competent
HIV-1 clones containing either no vif (ΔVif) or vif from different SIV lineages (SIVcpz, SIVsab,
SIVrcm, or SIVsmm) as described in the methods.
(TIF)
S6 Fig. SIVsab Vif in a replication-competent lentivirus is a potent antagonist of AGM
APOBEC3G. Replication-competent HIV-1 proviral plasmids without vif (- Vif) or encoding
vif from SIVcpz (SIVcpz Vif) or SIVsab (SIVsab Vif) (i.e. the same proviral plasmids used in
Fig 3) were transfected into 293T cells along with no APOBEC3G or APOBEC3G from African
green monkeys (A3G haplotype VIII [17]). The supernatants were collected two days after
transfection, p24gag amount was determined, and were used to determine infectious titers on
TZM-bl cells. Infectivity (infectious units per ng of p24gag) in the absence of APOBEC3G was
normalized to 100%. The graphs show the infectivity values for the average of two infections;
error bars indicate the SD from the mean of these replicates. The results show that the SIVsab
Vif encoded in a replication-competent HIV-1 provirus is able to fully overcome an AGM
APOBEC3G, while SIVcpz Vif is able to only partially antagonize it.
(TIF)
S7 Fig. Confirmation of chimpanzee APOBEC3 variants by Sanger sequencing. A selection
of polymorphic positions was used to confirm the deep sequencing analyses by Sanger
sequencing. All SNPs tested (n = 16) were confirmed, including heterozygous and homozygous
positions. A-C, Here is a representative selection.
(TIF)
S1 Dataset. Txt file with polymorphisms found in Pan APOBEC3D. Sequencing reads from
[34].
(TXT)
S2 Dataset. Txt file with polymorphisms found in Pan APOBEC3F. Sequencing reads from
[34].
(TXT)
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S3 Dataset. Txt file with polymorphisms found in Pan APOBEC3G. Sequencing reads from
[34].
(TXT)
S4 Dataset. Txt file with polymorphisms found in Pan APOBEC3H. Sequencing reads from
[34].
(TXT)
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